Merck stops development of combination diabetes drug

11/19/2012 | Reuters

Merck & Co. cited business reasons in its decision to stop development of a diabetes pill that would have combined its Januvia and a generic version of Lipitor, Pfizer's cholesterol drug. Drugmakers see combination drugs as a way to reduce the number of medications patients take. Merck already markets Juvisync, which is Januvia plus the cholesterol drug simvastatin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ